Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851383 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00851383 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 56 participants.
The verdict
NCT00851383, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of Ad35-GRIN/ENV HIV vaccine and Ad35-GRIN HIV vaccine administered intramuscularly at 0 and 6 months.
Interventions
- BIOLOGICAL Ad35-GRIN/ENV
- BIOLOGICAL Ad35-GRIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851383
The ClinicalTrials.gov registry entry for NCT00851383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ad35-GRIN/ENV is the first listed.
NCT00851383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00851383 about?
NCT00851383 is a clinical study titled "A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers". The purpose of this study is to evaluate the safety and immunogenicity of Ad35-GRIN/ENV HIV vaccine and Ad35-GRIN HIV vaccine administered intramuscularly at 0 and 6 months.
What is the current status of trial NCT00851383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2009-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00851383?
The interventions under investigation include: Ad35-GRIN/ENV (BIOLOGICAL), Ad35-GRIN (BIOLOGICAL).
Who is sponsoring clinical trial NCT00851383?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.